Day 1 after diabetes drug Empagliflozin goes off patent, generics go to town with it
Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin – on day one after the innovative drug from Boehringer Ingelheim (BI) went
Glenmark expands diabetes portfolio with new Empagliflozin treatments
Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of
